



Repare Therapeutics Inc.
PFIC Annual Information Statement

Repare Therapeutics Inc. (the “Company”) believes that it was classified as a passive foreign investment company (“PFIC”) ¹ for the taxable year beginning January 1, 2023 and ending on December 31, 2023. This PFIC Annual Information Statement contains information to enable you, should you so choose based on the advice of your tax advisors in light of your tax circumstances, to elect to treat the Company as a qualified electing fund (“QEF”).

An election to treat the Company as a QEF is optional and generally remains in effect unless revoked with the consent of the Internal Revenue Service. The election, can only be made by a shareholder and may have significant United States federal and state tax consequences including current or future-year income inclusions. The Company is not providing any tax advice to any shareholder and is unable to make this election on behalf of a shareholder.

THE INFORMATION INCLUDED IN THIS LETTER AND IN THE PFIC STATEMENT ATTACHED DOES NOT CONSTITUTE TAX ADVICE. THE U.S. TAX LAWS REGARDING PFICS ARE EXTREMELY COMPLEX AND SHAREHOLDERS ARE STRONGLY ADVISED TO CONSULT WITH THEIR OWN TAX ADVISORS CONCERNING THE OVERALL TAX CONSEQUENCES OF THE OWNERSHIP OF OUR SHARES ARISING IN THEIR OWN PARTICULAR SITUATIONS UNDER UNITED STATES FEDERAL, STATE, LOCAL OR FOREIGN LAW AS WELL AS TO DETERMINE APPROPRIATE REPORTING OBLIGATIONS.

¹ Terms used herein shall have the meanings ascribed to them in, and shall be interpreted in accordance with, the applicable U.S. federal income tax law and regulations, including the United States Internal Revenue Code of 1986, as amended (the “Code”).



PFIC Annual Information Statement for:

**Repare Therapeutics Inc. (the "Company")
7171 Frederick Banting, Building 2, Suite 270, Saint-Laurent, Quebec H4S 1Z9**

1	Annual Statement for the Company's taxable year ending:	December 31, 2023
2	The Company's ordinary earnings/(losses) per share, per day*:	(\$0.0018251060)
3	The Company's long-term capital gain per, per day*:	Nil
	Of the amount noted above on line 3 as long-term capital gain, the following amount should be treated as ordinary income for investors for which IRC Section 1061 is applicable	Nil
4	Cash or property distributed or deemed to be distributed during the taxable year:	None

The Company will permit the holder to inspect and copy its permanent books of account, records, and such other documents as may be maintained by the Company that are necessary to establish that the Company's ordinary earnings and net capital gain, as defined in Treasury Regulations § 1.1293-1(a)(2), are computed in accordance with U.S. income tax principles, and verify these amounts and the holder's pro rata shares thereof.

Signed by:

Steve Forte
Executive Vice President and Chief Financial Officer
Repare Therapeutics Inc.
April 4, 2024

* To determine your pro rata share for the year, multiply the per share, per day figure by the number of shares of the Company you owned by the number of days the share(s) were held during your taxable year.